628 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Lilly's Emgality Gets FDA Approval for Cluster Headache http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-ZC-FT-425463 Jun 06, 2019 - Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down http://www.zacks.com/stock/news/424593/celldex-presents-data-from-cdx-3379-study-at-asco-stock-down?cid=CS-ZC-FT-424593 Jun 04, 2019 - Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy https://www.fool.com/investing/2019/05/28/this-just-in-goldman-sachs-picks-4-big-pharma-stoc.aspx?source=iedfolrf0000001 May 28, 2019 - And the analyst really likes one in particular.
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-ZC-FT-420060 May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
3 Tech Stocks for Growth Investors to Buy Right Now http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-ZC-FT-418127 May 22, 2019 - Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/416747/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-416747 May 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

Pages: 1234567891011...63

<<<Page 6>